Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 52-58

  Duarte, R F ^a   Shaw, B E ^b   Marin P ^c   Kottaridis, P ^d   Ortiz, M ^e   Morante, C ^f   Delgado, J ^g   Gayoso, J ^h   Goterriz, R ⁱ   Martinez Chamorro C ^j   Mateos Mazon J J ^k   Ramirez C ^l   De La Rubia, J ^m   Achtereekte, H ⁿ   Gandhi, P J ⁿ   Douglas, K W ^o   Russell, N H ^p  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL QUIRÓN   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

^l HOSPITAL JUAN CANALEJO   (Spain)

^m HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁿ GENZYME CORPORATION   (United States)

^o BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^p NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

AMD3100; autologous transplantation; mobilization; PBSC; plerixafor

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTEROPATHY; EVENING DOSAGE; FEMALE; FLATULENCE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MORNING DOSAGE; MULTIPLE MYELOMA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPAIN; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; UNITED KINGDOM;

ADULT; AGED; ANTIGENS, CD34; COHORT STUDIES; COMPASSIONATE USE TRIALS; DRUG THERAPY, COMBINATION; EUROPEAN UNION; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 78651347616     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.54     Document Type: Article

References (30)

1. Gratwohl A, Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol 2009; 16: 420-426.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Villanueva ML, Vose JM. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2006; 4: 521-530.
4. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
5. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
6. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
7. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
8. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
9. Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J et al. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007; 40: 437-441.
10. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
11. Bender JG, To LB, William S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
12. Villalon L, Odriozola J, Larana JG, Zamora C, Pérez de Oteyza J, Jodra MH et al. Autologous peripheral blood progenitor cell transplantation with < 2 × 10(6) CD34(+)/kg: An analysis of variables concerning mobilisation and engraftment. Hematol J 2000; 1: 374-381.
13. Dreger P, Kloss M, Petersen B, Haferlach T, Löffler H, Loeffler M et al. Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cells but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
14. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: An indication for patients at risk for low mobilization. Bone Marrow Transplant 2002; 30: 725-732.
15. Pusic I, Jiang YJ, Landua S, Uy GL, Rettig MP, Cashen AF et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
16. Rettig MP, Ramírez P, Nervi B, DiPersio JF. CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol 2009; 460: 57-90.
17. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
18. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized doubleblind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non- Hodgkin lymphoma. J Clin Oncol 2009; 27: 4767-4773.
19. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042.
20. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplant 2008; 41: 331-338.
21. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): An institutional experience. Bone Marrow Transplant 2009; 43: 909-917.
22. Weaver CH, Tauer K, Zhen B, Schwartzberg LS, Hazelton B, Weaver Z et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241-249.
23. Fraipont V, Sautois B, Baudoux E, Pereira M, Fassotte MF, Hermane JP et al. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion 2000; 40: 339-347.
24. Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003.
25. Goterris R, Hernandez-Boluda JC, Teruel A, Gomez C, Lis MJ, Terol MJ et al. Impact of different strategies of second line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847-853.
26. Pusic I, Jiang YJ, Landua S, Uy GL, Rettig MP, Cashen AF et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
27. Lefrere F, Levy V, Makke J, Audat F, Cavazzana-Calvo M, Miclea JM. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica 2004; 89: 1532-1534.
28. Gabriel IH, Sharon J, Olavarria E, Rahemtulla A, Kanfer E, Marin D et al. Efficacy, complication rates, and cost effectiveness of chemotherapy plus granulocyte colony stimulating factor conditioned mobilisation of peripheral blood haematopoietic stem cells in over 150 patients with haematological malignancies. Blood 2008; 112: S2378.
29. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667-1673.
30. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S et al. AMD3100 HIV Study Group. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-infection. J Accquir Immune Defic Syndr 2004; 37: 1253-1262.